Mona S. Abdellateif
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Mona S. Abdellateif has a total of 199 co-authors. Here are the top co-authors by number of shared publications:
- Abdel-Rahman Nabawy Zekri
Virology and Immunology Unit, Cancer Biology Department, National Cancer Institute, Cairo University, Cairo 11976, Egypt
10 shared publications - Abeer Ahmad Bahnassy
Tissue Culture and Cytogenetics Unit, Pathology Department, National Cancer Institute, Cairo University, Cairo, Egypt
10 shared publications Eman Z. Kandeel
Clinical Pathology Department, National Cancer Institute, Cairo University, Cairo, Egypt
8 shared publicationsLobna Refaat
Clinical Pathology Department, National Cancer Institute, Cairo University, Cairo, Egypt
7 shared publicationsMarwa Mohanad
Biochemistry Department, College of Pharmaceutical Sciences and Drug Manufacturing, MISR University for Science and Technology, 6th October, Egypt
7 shared publicationsNaglaa M. Hassan
Department of Clinical Pathology, National Cancer Institute, Cairo University, Cairo, 11976, Egypt
7 shared publications
Latest Publications
- 3 July 2026
- Published by Springer Nature in Molecular Biology Reports
- Vol. 53 (1)
The potential anticancer effect of Jasonia montana against hepatocellular carcinoma
Hepatocellular Carcinoma (HCC) is a fundamental health problem with an overall poor prognosis. Jasonia montana (J. montana) was evaluated for its biological activities against HCC cells (in vitro study). The efficacy of J. montana was evaluated for its cytotoxic activity on HepG2 cells. Its impacts on cell cycle phases, apoptosis pathways, DNA damage, cellular oxidative stress, and inflammation were assessed. Additionally, the expression levels of PTEN and SOX2 were also evaluated. The ethanol extract of J. montana produced a cytotoxic effect on HepG2 cells at (IC50) of 24 μg/mL. There was a significant increase in the cell number in the 2n, G0/G1, and G2/M phases (p < 0.001, p = 0.001, and p = 0.022; respectively), while a significant decrease in the cell number in the S phase (p < 0.001) and 4n phase (p = 0.011) compared to the untreated HepG2 cells. Caspase-8 [2.6 ± 0.56 ng/mL versus 0.9 ± 0.06 ng/mL, p < 0.001], Caspase-9 [11.9 ± 1.18 ng/mL versus 5.8 ± 0.85 ng/mL, p < 0.001], and Caspase-3 [19.9 ± 1.01 ng/mL versus 4.0 ± 0.88 ng/mL, p < 0.001] were significantly increased in HepG2 cells treated with J. montana compared to untreated control cells. There was a significant increase in the PTEN expression (FC = 3.04 ± 0.85, p = 0.030), and a significant decrease in SOX2 expression (FC = 0.54 ± 0.02, p = 0.039). There was a significant decrease in IL-6 and TNF-α levels (P < 0.001). Moreover, the total antioxidant (TA) and glutathione reductase (GSH) were significantly increased (P < 0.001). J. montana could be a potentially useful chemotherapeutic agent against HCC cells.
- 3 July 2026
- Published by Springer Nature in Molecular Biology Reports
- Vol. 53 (1)
The potential anticancer effect of Jasonia montana against hepatocellular carcinoma
Hepatocellular Carcinoma (HCC) is a fundamental health problem with an overall poor prognosis. Jasonia montana (J. montana) was evaluated for its biological activities against HCC cells (in vitro study). The efficacy of J. montana was evaluated for its cytotoxic activity on HepG2 cells. Its impacts on cell cycle phases, apoptosis pathways, DNA damage, cellular oxidative stress, and inflammation were assessed. Additionally, the expression levels of PTEN and SOX2 were also evaluated. The ethanol extract of J. montana produced a cytotoxic effect on HepG2 cells at (IC50) of 24 μg/mL. There was a significant increase in the cell number in the 2n, G0/G1, and G2/M phases (p < 0.001, p = 0.001, and p = 0.022; respectively), while a significant decrease in the cell number in the S phase (p < 0.001) and 4n phase (p = 0.011) compared to the untreated HepG2 cells. Caspase-8 [2.6 ± 0.56 ng/mL versus 0.9 ± 0.06 ng/mL, p < 0.001], Caspase-9 [11.9 ± 1.18 ng/mL versus 5.8 ± 0.85 ng/mL, p < 0.001], and Caspase-3 [19.9 ± 1.01 ng/mL versus 4.0 ± 0.88 ng/mL, p < 0.001] were significantly increased in HepG2 cells treated with J. montana compared to untreated control cells. There was a significant increase in the PTEN expression (FC = 3.04 ± 0.85, p = 0.030), and a significant decrease in SOX2 expression (FC = 0.54 ± 0.02, p = 0.039). There was a significant decrease in IL-6 and TNF-α levels (P < 0.001). Moreover, the total antioxidant (TA) and glutathione reductase (GSH) were significantly increased (P < 0.001). J. montana could be a potentially useful chemotherapeutic agent against HCC cells.
- 25 June 2026
- Published by Springer Nature in Journal of Hematopathology
- Vol. 19 (1)
Bone marrow hemophagocytosis in patients with hematological malignancies and COVID-19 infections: mimicry or secondary HLH?
Severe coronavirus disease 2019 (COVID-19) and secondary hemophagocytic lymphohistiocytosis (sHLH) share overlapping pathogenesis, symptoms, and ultimately fatal outcomes unless prompt early interventions are undertaken. The excessive immune response in COVID-19 may increase hemophagocytes in bone marrow aspirate (BMA), which could mimic sHLH. We aimed to assess hemophagocytic cells in the BM of COVID-19 patients with hematological neoplasms and examine their link to sHLH. BMAs from 44 living COVID-19-positive patients with hematological neoplasms were examined, focusing on the presence of hemophagocytic cells. Alongside clinical and laboratory data, patients were classified into two groups according to the HLH-2004 diagnostic criteria: those meeting ≥ 4 criteria (n = 23) and those meeting < 4 criteria (n = 21). BMAs from 44 COVID-19-negative patients with similar hematological malignancies were also analyzed for comparison. Hemophagocytic cells were present in 33/44 (75.0%) COVID-19-positive patients and were associated with normal and increased erythropoiesis (p = 0.044). Hemophagocytosis was significantly more frequent in COVID-19-positive than in COVID-19-negative patients (p < 0.001). Meeting ≥ 4 HLH-2004 criteria was significantly more prevalent in newly diagnosed patients than in those during follow-up/relapse (p = 0.004). Significantly higher H-scores were also observed in newly diagnosed patients compared with those in follow-up (p < 0.001). Patients with severe/critical COVID-19 or intensive care unit (ICU) admission had higher H-scores; however, the differences were not statistically significant (p = 0.509 and 0.246, respectively). Hemophagocytic cells are significantly observed in COVID-19 patients with hematological neoplasms, but are insufficient to support a classic diagnosis of concurrent sHLH. These findings suggest that COVID-19-associated hyperinflammation may contribute to BM hemophagocytosis in this vulnerable population.
- 25 June 2026
- Published by Springer Nature in Journal of Hematopathology
- Vol. 19 (1)
Bone marrow hemophagocytosis in patients with hematological malignancies and COVID-19 infections: mimicry or secondary HLH?
Severe coronavirus disease 2019 (COVID-19) and secondary hemophagocytic lymphohistiocytosis (sHLH) share overlapping pathogenesis, symptoms, and ultimately fatal outcomes unless prompt early interventions are undertaken. The excessive immune response in COVID-19 may increase hemophagocytes in bone marrow aspirate (BMA), which could mimic sHLH. We aimed to assess hemophagocytic cells in the BM of COVID-19 patients with hematological neoplasms and examine their link to sHLH. BMAs from 44 living COVID-19-positive patients with hematological neoplasms were examined, focusing on the presence of hemophagocytic cells. Alongside clinical and laboratory data, patients were classified into two groups according to the HLH-2004 diagnostic criteria: those meeting ≥ 4 criteria (n = 23) and those meeting < 4 criteria (n = 21). BMAs from 44 COVID-19-negative patients with similar hematological malignancies were also analyzed for comparison. Hemophagocytic cells were present in 33/44 (75.0%) COVID-19-positive patients and were associated with normal and increased erythropoiesis (p = 0.044). Hemophagocytosis was significantly more frequent in COVID-19-positive than in COVID-19-negative patients (p < 0.001). Meeting ≥ 4 HLH-2004 criteria was significantly more prevalent in newly diagnosed patients than in those during follow-up/relapse (p = 0.004). Significantly higher H-scores were also observed in newly diagnosed patients compared with those in follow-up (p < 0.001). Patients with severe/critical COVID-19 or intensive care unit (ICU) admission had higher H-scores; however, the differences were not statistically significant (p = 0.509 and 0.246, respectively). Hemophagocytic cells are significantly observed in COVID-19 patients with hematological neoplasms, but are insufficient to support a classic diagnosis of concurrent sHLH. These findings suggest that COVID-19-associated hyperinflammation may contribute to BM hemophagocytosis in this vulnerable population.
- Open Access
- 9 April 2026
- Published by Springer Nature in Scientific Reports
- Vol. 16 (1)
The potential directing role of chemokines for specific metastatic sites in breast cancer
Metastasis is the most life-threatening sequel in breast cancer (BC). The aim of the study is to assess the association of certain cytokines including IL4, IL-11, CCL-2, CCL-4, and CXCL12 with the site of metastases (lung, bone, brain, ovaries, and liver) in BC. The serum levels of IL4, IL-11, CCL-2, CCL4 and CXCL-12 were assessed in 175 BC patients compared to 50 control subjects using ELISA. The data were correlated to the sites of metastases, patients’ clinicopathological features and response to treatment. The mean age of the BC patients was 49.3 ± 9.5 years old. Distant metastasis was found in 69.1% (121/175) of the patients. There was a significant increase in IL4 ( p = 0.012 ), CXCL12 ( p < 0.001 ), and CCL4 ( p < 0.001 ) in BC patients compared to controls. Lung metastasis associated significantly with increased IL11 concentration (OR = 1.008, p = 0.023). Brain metastasis associated with increased IL4 (OR = 1.009, p = 0.025), and CXCL12 concentrations (OR = 1.004, p = 0.031). Bone metastasis linked with CCL4 (OR = 0.991, p = 0.017) and CCL2 (OR = 0.996, p = 0.001). Low ER expression, brain, and liver metastasis were considered as potential independent risk factors for shorter disease-free survival (DFS) of BC patients ( p = 0.040 , 0.001 , and 0.003 ; respectively). IL4 (AUC = 0.699, p = 0.011) and CXCL12 (AUC = 0.700, p = 0.010) showed a diagnostic potential for BC brain metastasis. Combined expression of both IL4 and CXCL12 exhibited a 75% sensitivity and a 71.4% specificity (AUC = 0.768, p = 0.001). IL11 associated with the diagnosis of BC lung metastasis (AUC = 0.629, p = 0.024). While CCL2 showed a significant potential for the diagnosis of BC liver metastasis (AUC = 0.717, p = 0.006). Chemokines have an important role in directing the tumor cells and colonization in a specific metastatic site.
- 9 April 2026
- Published by Springer Nature in Scientific Reports
- Vol. 16 (1)
Open AccessThe potential directing role of chemokines for specific metastatic sites in breast cancer
Metastasis is the most life-threatening sequel in breast cancer (BC). The aim of the study is to assess the association of certain cytokines including IL4, IL-11, CCL-2, CCL-4, and CXCL12 with the site of metastases (lung, bone, brain, ovaries, and liver) in BC. The serum levels of IL4, IL-11, CCL-2, CCL4 and CXCL-12 were assessed in 175 BC patients compared to 50 control subjects using ELISA. The data were correlated to the sites of metastases, patients’ clinicopathological features and response to treatment. The mean age of the BC patients was 49.3 ± 9.5 years old. Distant metastasis was found in 69.1% (121/175) of the patients. There was a significant increase in IL4 ( p = 0.012 ), CXCL12 ( p < 0.001 ), and CCL4 ( p < 0.001 ) in BC patients compared to controls. Lung metastasis associated significantly with increased IL11 concentration (OR = 1.008, p = 0.023). Brain metastasis associated with increased IL4 (OR = 1.009, p = 0.025), and CXCL12 concentrations (OR = 1.004, p = 0.031). Bone metastasis linked with CCL4 (OR = 0.991, p = 0.017) and CCL2 (OR = 0.996, p = 0.001). Low ER expression, brain, and liver metastasis were considered as potential independent risk factors for shorter disease-free survival (DFS) of BC patients ( p = 0.040 , 0.001 , and 0.003 ; respectively). IL4 (AUC = 0.699, p = 0.011) and CXCL12 (AUC = 0.700, p = 0.010) showed a diagnostic potential for BC brain metastasis. Combined expression of both IL4 and CXCL12 exhibited a 75% sensitivity and a 71.4% specificity (AUC = 0.768, p = 0.001). IL11 associated with the diagnosis of BC lung metastasis (AUC = 0.629, p = 0.024). While CCL2 showed a significant potential for the diagnosis of BC liver metastasis (AUC = 0.717, p = 0.006). Chemokines have an important role in directing the tumor cells and colonization in a specific metastatic site.
- Open Access
- 20 December 2025
- Published by Baishideng Publishing Group Inc. in World Journal of Experimental Medicine
- Vol. 15 (4)
Ferula assafoetida induced colon cancer cells differentiation through JNK/MAPK signalling pathway activation
BACKGROUND Colon cancer is a major health problem with increasing mortality rates worldwide. AIM To evaluate the ability of Ferula assafoetida (F. assafoetida ) to induce differentiation of colon cancer cells to function as normal cells. METHODS The cytotoxic effect of F. assafoetida was assessed against Caco cells using the (3-(4,5-dimethylthiazol-2-yl)-2,5-diphe nyltetrazoliumbromide thiazolyl assay. Cell cycle analysis and apoptosis were assessed using CytellTM cell system. The total antioxidant (TA), glutathione (GSH), malondialdehyde (MDA) concentrations, and alkaline phosphatase (ALP) activity were also assessed. The c-Jun N-terminal kinases (JNKs) and mitogen-activated protein kinase (MAPK) expressions were evaluated using quantitative real-time polymerase chain reaction. RESULTS There was a significant increase in the cell number treated with F. assafoetida (53.85% ± 0.03%), and those treated with sodium butyrate (NaBT) (54.6% ± 0.10%) in sub-G1 phase, compared to the untreated cells (0.78% ± 0.03%, P < 0.001). Apoptosis was significantly increased in the Caco cells treated with F. assafoetida (49.1% ± 0.14%) compared to those treated with NaBT (27.3% ± 0.10%, P < 0.001), and untreated cells (11.1% ± 0.02%, P < 0.001). DNA degradation was observed in Caco cells treated with F. assafoetida in a dose-dependent manner, where complete degradation occurred at the dose of IC50 (342.9 μg/mL). F. assafoetida induced a significant increase in the TA concentration and GSH, while a significant decrease in the MDA levels (P < 0.001, for all). Also, there was a significant increase in ALP activity in Caco cells (0.53 ± 0.26 U/mL) compared to the control cells (0.05 ± 0.02 U/mL, P = 0.045). There was a significant upregulation of JNK and MAPK expression in Caco cells treated with F. assafoetida compared to the controls [2.59 ± 0.01 (P < 0.001), and 3.62 ± 0.01 (P < 0.001); respectively]. CONCLUSION F. assafoetida is a potentially successful therapeutic and differentiating agent for colon cancer.
- 20 December 2025
- Published by Baishideng Publishing Group Inc. in World Journal of Experimental Medicine
- Vol. 15 (4)
Open AccessFerula assafoetida induced colon cancer cells differentiation through JNK/MAPK signalling pathway activation
BACKGROUND Colon cancer is a major health problem with increasing mortality rates worldwide. AIM To evaluate the ability of Ferula assafoetida (F. assafoetida ) to induce differentiation of colon cancer cells to function as normal cells. METHODS The cytotoxic effect of F. assafoetida was assessed against Caco cells using the (3-(4,5-dimethylthiazol-2-yl)-2,5-diphe nyltetrazoliumbromide thiazolyl assay. Cell cycle analysis and apoptosis were assessed using CytellTM cell system. The total antioxidant (TA), glutathione (GSH), malondialdehyde (MDA) concentrations, and alkaline phosphatase (ALP) activity were also assessed. The c-Jun N-terminal kinases (JNKs) and mitogen-activated protein kinase (MAPK) expressions were evaluated using quantitative real-time polymerase chain reaction. RESULTS There was a significant increase in the cell number treated with F. assafoetida (53.85% ± 0.03%), and those treated with sodium butyrate (NaBT) (54.6% ± 0.10%) in sub-G1 phase, compared to the untreated cells (0.78% ± 0.03%, P < 0.001). Apoptosis was significantly increased in the Caco cells treated with F. assafoetida (49.1% ± 0.14%) compared to those treated with NaBT (27.3% ± 0.10%, P < 0.001), and untreated cells (11.1% ± 0.02%, P < 0.001). DNA degradation was observed in Caco cells treated with F. assafoetida in a dose-dependent manner, where complete degradation occurred at the dose of IC50 (342.9 μg/mL). F. assafoetida induced a significant increase in the TA concentration and GSH, while a significant decrease in the MDA levels (P < 0.001, for all). Also, there was a significant increase in ALP activity in Caco cells (0.53 ± 0.26 U/mL) compared to the control cells (0.05 ± 0.02 U/mL, P = 0.045). There was a significant upregulation of JNK and MAPK expression in Caco cells treated with F. assafoetida compared to the controls [2.59 ± 0.01 (P < 0.001), and 3.62 ± 0.01 (P < 0.001); respectively]. CONCLUSION F. assafoetida is a potentially successful therapeutic and differentiating agent for colon cancer.
- Open Access
- 14 November 2025
- Published by Springer Nature in Scientific Reports
- Vol. 15 (1) , 39967
Systemic inflammatory indices comprising monocytes provide a clinical significance for thyroid cancer identification
Is to assess the diagnostic and prognostic role of different inflammatory indices in patients with benign and malignant thyroid nodules. The neutrophil to lymphocyte ratio (NLR), lymphocyte to monocyte ratio (LMR), platelet to lymphocyte ratio (PLR), derived NLR (dNLR), systemic inflammation index (SII), neutrophil to lymphocyte, platelet ratio (NLPR), systemic inflammation response index (SIRI), and aggregate index of systemic inflammation (AISI) were assessed in150 thyroid cancer (TC) patients, 75 benign nodule patients, compared to 70 healthy controls. There was a significant difference among TC patients and control group regarding the PLR, LMR, SII, NLPR, SIRI, and AISI (p = 0.006, p < 0.001, p = 0.043,p < 0.001 p < 0.001, and p < 0.001; respectively). LMR and SIRI could efficiently differentiate malignant versus benign thyroid nodules at a cutoff of 5.2 and 0.597; respectively. LMR, PLR, SIRI, and AISI were notably associated with high-risk stratification of TC patients (p = 0.011, p = 0.035, p = 0.036, and p = 0.034; respectively). Moreover, PLR was significantly elevated in TC patients with lymph node (LN) metastasis (p = 0.010). The LMR (OR = 0.318, p < 0.001), SIRI (OR = 2.293, p = 0.001), AISI (OR = 2.714, p < 0.001), and FT4 (OR = 0.250, p < 0.001) could differentiate TC against non-TC groups. LMR, SIRI, AISI, and FT4 are independent risk factors for TC (p < 0.001, p = 0.030, p = 0.026, and p < 0.001; respectively). There was no significant impact of the assessed inflammatory indices on the disease-free survival of the patients. LMR, PLR, SII, NLPR, SIRI, and AISI could be potential supportive markers for TC diagnosis. LMR and SIRI could help in differentiating malignant versus benign thyroid nodules.
- 14 November 2025
- Published by Springer Nature in Scientific Reports
- Vol. 15 (1) , 39967
Open AccessSystemic inflammatory indices comprising monocytes provide a clinical significance for thyroid cancer identification
Is to assess the diagnostic and prognostic role of different inflammatory indices in patients with benign and malignant thyroid nodules. The neutrophil to lymphocyte ratio (NLR), lymphocyte to monocyte ratio (LMR), platelet to lymphocyte ratio (PLR), derived NLR (dNLR), systemic inflammation index (SII), neutrophil to lymphocyte, platelet ratio (NLPR), systemic inflammation response index (SIRI), and aggregate index of systemic inflammation (AISI) were assessed in150 thyroid cancer (TC) patients, 75 benign nodule patients, compared to 70 healthy controls. There was a significant difference among TC patients and control group regarding the PLR, LMR, SII, NLPR, SIRI, and AISI (p = 0.006, p < 0.001, p = 0.043,p < 0.001 p < 0.001, and p < 0.001; respectively). LMR and SIRI could efficiently differentiate malignant versus benign thyroid nodules at a cutoff of 5.2 and 0.597; respectively. LMR, PLR, SIRI, and AISI were notably associated with high-risk stratification of TC patients (p = 0.011, p = 0.035, p = 0.036, and p = 0.034; respectively). Moreover, PLR was significantly elevated in TC patients with lymph node (LN) metastasis (p = 0.010). The LMR (OR = 0.318, p < 0.001), SIRI (OR = 2.293, p = 0.001), AISI (OR = 2.714, p < 0.001), and FT4 (OR = 0.250, p < 0.001) could differentiate TC against non-TC groups. LMR, SIRI, AISI, and FT4 are independent risk factors for TC (p < 0.001, p = 0.030, p = 0.026, and p < 0.001; respectively). There was no significant impact of the assessed inflammatory indices on the disease-free survival of the patients. LMR, PLR, SII, NLPR, SIRI, and AISI could be potential supportive markers for TC diagnosis. LMR and SIRI could help in differentiating malignant versus benign thyroid nodules.
- Open Access
- 20 September 2025
- Published by Baishideng Publishing Group Inc. in World Journal of Experimental Medicine
- Vol. 15 (3)
Clinical significance of differential plasma proteins levels in the diagnosis of epithelial ovarian cancer
BACKGROUND Ovarian cancer (OC) is the most lethal gynecological cancer among females, and its early diagnosis could help for better outcomes of the patients. AIM To investigate the utility of serum insulin-like growth factors-binding proteins 2 (IGFBP2), secreted phosphoprotein 1 (SPP1), thrombospondin 1 protein (TSP1) and D-dimer levels in addition to currently used biomarkers [cancer antigen 125 (CA125) and human epididymis protein 4 (HE4)] in the diagnosis of epithelial OC (EOC). METHODS This is a case-control study that included fifty females diagnosed with EOC, 10 females with benign ovarian masses recruited from the Egyptian National Cancer Institute, and 30 healthy females as a control group. All subjects were assessed for serum HE4, CA125, IGFBP2, TSP1 and SPP1 measurement by enzyme-linkedimmunosorbent assay. RESULTS There was a statistically significant difference in serum levels between EOC, benign ovarian masses, and healthy control groups regarding CA125 and SPP1 (P < 0.001 for both markers), while HE4 and IGFBP2 increased significantly in EOC compared to healthy control groups (P < 0.001 for all markers) with no significant difference between EOC and benign ovarian masses groups. However, there was no statistically significant difference among EOC, benign ovarian masses, and healthy control groups regarding the TSP1 serum levels (P = 0.051). Receiver operating characteristic analysis revealed that combined assessment of SPP1 with CA125 or TSP1 increased the diagnosis of EOC patients to a sensitivity, specificity, and area under curve of (93.3%, 100%, 0.968; respectively, P < 0.001). CONCLUSION SPP1 may be a potential marker for the differentiation between benign and malignant ovarian masses, while IGFBP2 can differentiate between healthy females and females with ovarian masses. Combining SPP1 with CA125 or TSP1 provides high sensitivity and specificity for the detection of EOC patients.
- 20 September 2025
- Published by Baishideng Publishing Group Inc. in World Journal of Experimental Medicine
- Vol. 15 (3)
Open AccessClinical significance of differential plasma proteins levels in the diagnosis of epithelial ovarian cancer
BACKGROUND Ovarian cancer (OC) is the most lethal gynecological cancer among females, and its early diagnosis could help for better outcomes of the patients. AIM To investigate the utility of serum insulin-like growth factors-binding proteins 2 (IGFBP2), secreted phosphoprotein 1 (SPP1), thrombospondin 1 protein (TSP1) and D-dimer levels in addition to currently used biomarkers [cancer antigen 125 (CA125) and human epididymis protein 4 (HE4)] in the diagnosis of epithelial OC (EOC). METHODS This is a case-control study that included fifty females diagnosed with EOC, 10 females with benign ovarian masses recruited from the Egyptian National Cancer Institute, and 30 healthy females as a control group. All subjects were assessed for serum HE4, CA125, IGFBP2, TSP1 and SPP1 measurement by enzyme-linkedimmunosorbent assay. RESULTS There was a statistically significant difference in serum levels between EOC, benign ovarian masses, and healthy control groups regarding CA125 and SPP1 (P < 0.001 for both markers), while HE4 and IGFBP2 increased significantly in EOC compared to healthy control groups (P < 0.001 for all markers) with no significant difference between EOC and benign ovarian masses groups. However, there was no statistically significant difference among EOC, benign ovarian masses, and healthy control groups regarding the TSP1 serum levels (P = 0.051). Receiver operating characteristic analysis revealed that combined assessment of SPP1 with CA125 or TSP1 increased the diagnosis of EOC patients to a sensitivity, specificity, and area under curve of (93.3%, 100%, 0.968; respectively, P < 0.001). CONCLUSION SPP1 may be a potential marker for the differentiation between benign and malignant ovarian masses, while IGFBP2 can differentiate between healthy females and females with ovarian masses. Combining SPP1 with CA125 or TSP1 provides high sensitivity and specificity for the detection of EOC patients.
- Open Access
- 24 June 2025
- Published by Baishideng Publishing Group Inc. in World Journal of Clinical Oncology
- Vol. 16 (6) , 107271
Clinical significance of the transcription factor (SOX11) expression in the bone marrow of acute myeloid leukemia patients
BACKGROUND The prognosis for acute myeloid leukemia (AML) remains poor, underscoring the need for a deeper understanding of its underlying molecular mechanisms. AIM To assess the significance of SOX11 gene expression in the clinical features, response to treatment, and survival outcomes of adult patients with AML. METHODS This retrospective study enrolled 102 adults with AML. SOX11 gene expression in bone marrow samples was measured using real-time PCR. Data were correlated to the patients’ clinical features, response to treatment, and survival rates. RESULTS Increased SOX11 expression was significantly associated with the presence of the FLT3-ITD mutation (P < 0.001), the FAB-M2 subtype (P = 0.008), and cytogenetic abnormalities (P = 0.011). However, no significant association was found between SOX11 expression and other clinical laboratory parameters, complete remission, disease-free survival, or overall survival. CONCLUSION SOX11 expression may serve as a marker to identify specific subsets of AML patients who could benefit from intensive targeted chemotherapy.
- 24 June 2025
- Published by Baishideng Publishing Group Inc. in World Journal of Clinical Oncology
- Vol. 16 (6) , 107271
Open AccessClinical significance of the transcription factor (SOX11) expression in the bone marrow of acute myeloid leukemia patients
BACKGROUND The prognosis for acute myeloid leukemia (AML) remains poor, underscoring the need for a deeper understanding of its underlying molecular mechanisms. AIM To assess the significance of SOX11 gene expression in the clinical features, response to treatment, and survival outcomes of adult patients with AML. METHODS This retrospective study enrolled 102 adults with AML. SOX11 gene expression in bone marrow samples was measured using real-time PCR. Data were correlated to the patients’ clinical features, response to treatment, and survival rates. RESULTS Increased SOX11 expression was significantly associated with the presence of the FLT3-ITD mutation (P < 0.001), the FAB-M2 subtype (P = 0.008), and cytogenetic abnormalities (P = 0.011). However, no significant association was found between SOX11 expression and other clinical laboratory parameters, complete remission, disease-free survival, or overall survival. CONCLUSION SOX11 expression may serve as a marker to identify specific subsets of AML patients who could benefit from intensive targeted chemotherapy.
- Open Access
- 27 May 2025
- Published by Springer Nature in Journal of the Egyptian National Cancer Institute
- Vol. 37 (1) , 1-9
The decay-accelerating factor (CD55) in acute leukemia patients and its query implication in cancer pathogenesis
Background: The role of the complement system and its membrane-bound regulatory proteins (mCRPs) in the pathogenesis of cancer is still a debatable issue. The current study aimed to evaluate the role of the complement regulatory protein, the decay-accelerating factor (CD55), in the pathogenesis of acute leukemia. Methods: CD55 gene expression was assessed in the peripheral blood of 34 patients with acute myeloid leukemia (AML), 26 patients with acute lymphoblastic leukemia (ALL), and 30 healthy controls by qRT-PCR. Also, CD55 gene knockdown was performed in HSB-2 (ALL cell line) using customized short hairpin RNA (shRNA). Flowcytometric analysis was done to ensure successful transfection, and MTT assay was performed to evaluate the cell viability post-transfection and silencing of CD55. Results: There was a significant downregulation of CD55 in acute leukemia patients compared to the healthy controls (p < 0.001) with RQ values of AML, and ALL patients were 0.2499 ± 0.07427 and 0.2581 ± 0.09467, respectively. The MTT assay showed a significantly reduced viability of HSB-2 cells following posttranscriptional silencing of CD55 (p < 0.001) by 78.6% as compared to the non-transfected or mock-transfected cells. In the presence of human serum, there was a significant reduction in cell viability by 66.3% as compared to non-transfected controls (p = 0.01). Regarding the cells co-transfected with CD55 and CD46 silencing plasmids, cell viability was significantly decreased by 70.6% compared to non-transfected cells. Conclusion: CD55 was significantly downregulated in acute leukemia. However, its in vitro silencing showed significant reduction in cell viability, giving it a dual opposing role in cancer.
- 27 May 2025
- Published by Springer Nature in Journal of the Egyptian National Cancer Institute
- Vol. 37 (1) , 1-9
Open AccessThe decay-accelerating factor (CD55) in acute leukemia patients and its query implication in cancer pathogenesis
Background: The role of the complement system and its membrane-bound regulatory proteins (mCRPs) in the pathogenesis of cancer is still a debatable issue. The current study aimed to evaluate the role of the complement regulatory protein, the decay-accelerating factor (CD55), in the pathogenesis of acute leukemia. Methods: CD55 gene expression was assessed in the peripheral blood of 34 patients with acute myeloid leukemia (AML), 26 patients with acute lymphoblastic leukemia (ALL), and 30 healthy controls by qRT-PCR. Also, CD55 gene knockdown was performed in HSB-2 (ALL cell line) using customized short hairpin RNA (shRNA). Flowcytometric analysis was done to ensure successful transfection, and MTT assay was performed to evaluate the cell viability post-transfection and silencing of CD55. Results: There was a significant downregulation of CD55 in acute leukemia patients compared to the healthy controls (p < 0.001) with RQ values of AML, and ALL patients were 0.2499 ± 0.07427 and 0.2581 ± 0.09467, respectively. The MTT assay showed a significantly reduced viability of HSB-2 cells following posttranscriptional silencing of CD55 (p < 0.001) by 78.6% as compared to the non-transfected or mock-transfected cells. In the presence of human serum, there was a significant reduction in cell viability by 66.3% as compared to non-transfected controls (p = 0.01). Regarding the cells co-transfected with CD55 and CD46 silencing plasmids, cell viability was significantly decreased by 70.6% compared to non-transfected cells. Conclusion: CD55 was significantly downregulated in acute leukemia. However, its in vitro silencing showed significant reduction in cell viability, giving it a dual opposing role in cancer.
- Open Access
- 20 March 2025
- Published by Baishideng Publishing Group Inc. in World Journal of Experimental Medicine
- Vol. 15 (1) , 99516
Prevalence of RUNX1 gene alterations in de novo adult acute myeloid leukemia
BACKGROUND Acute myeloid leukemia (AML) is a complicated disease with uncontrolled hematopoietic precursor proliferation induced by various genetic alterations. Runt-related transcription factor-1 (RUNX1 ) is commonly disrupted by chromosomal translocations in hematological malignancies. AIM To characterize RUNX1 gene rearrangements and copy number variations in newly diagnosed adult AML patients, with an emphasis on the impact of clinical and laboratory features on the outcome. METHODS Fluorescence in situ hybridization was used to test RUNX1 gene alterations in 77 newly diagnosed adult AML cases. NPM1 , FLT3/ITD , FLT3/TKD , and KIT mutations were tested by PCR. Prognostic clinical and laboratory findings were studied in relation to RUNX1 alterations. RESULTS RUNX1 abnormalities were detected by fluorescence in situ hybridization in 41.6% of patients: 20.8% had translocations, 22.1% had amplification, and 5.2% had deletion. Translocations prevailed in AML-M2 (P = 0.019) with a positive expression of myeloperoxidase (P = 0.031), whereas deletions dominated in M4 and M5 subtypes (P = 0.008) with a positive association with CD64 expression (P = 0.05). The modal chromosomal number was higher in cases having amplifications (P = 0.007) and lower in those with deletions (P = 0.008). RUNX1 abnormalities were associated with complex karyotypes (P < 0.001) and were mutually exclusive of NPM1 mutations. After 44 months of follow-up, RUNX1 abnormalities affected neither patients’ response to treatment nor overall survival. CONCLUSION RUNX1 abnormalities were mutually exclusive of NPM1 mutations. RUNX1 abnormalities affected neither patients’ response to treatment nor overall survival.
- 20 March 2025
- Published by Baishideng Publishing Group Inc. in World Journal of Experimental Medicine
- Vol. 15 (1) , 99516
Open AccessPrevalence of RUNX1 gene alterations in de novo adult acute myeloid leukemia
BACKGROUND Acute myeloid leukemia (AML) is a complicated disease with uncontrolled hematopoietic precursor proliferation induced by various genetic alterations. Runt-related transcription factor-1 (RUNX1 ) is commonly disrupted by chromosomal translocations in hematological malignancies. AIM To characterize RUNX1 gene rearrangements and copy number variations in newly diagnosed adult AML patients, with an emphasis on the impact of clinical and laboratory features on the outcome. METHODS Fluorescence in situ hybridization was used to test RUNX1 gene alterations in 77 newly diagnosed adult AML cases. NPM1 , FLT3/ITD , FLT3/TKD , and KIT mutations were tested by PCR. Prognostic clinical and laboratory findings were studied in relation to RUNX1 alterations. RESULTS RUNX1 abnormalities were detected by fluorescence in situ hybridization in 41.6% of patients: 20.8% had translocations, 22.1% had amplification, and 5.2% had deletion. Translocations prevailed in AML-M2 (P = 0.019) with a positive expression of myeloperoxidase (P = 0.031), whereas deletions dominated in M4 and M5 subtypes (P = 0.008) with a positive association with CD64 expression (P = 0.05). The modal chromosomal number was higher in cases having amplifications (P = 0.007) and lower in those with deletions (P = 0.008). RUNX1 abnormalities were associated with complex karyotypes (P < 0.001) and were mutually exclusive of NPM1 mutations. After 44 months of follow-up, RUNX1 abnormalities affected neither patients’ response to treatment nor overall survival. CONCLUSION RUNX1 abnormalities were mutually exclusive of NPM1 mutations. RUNX1 abnormalities affected neither patients’ response to treatment nor overall survival.
- Open Access
- 19 March 2025
- Published by Springer Nature in Molecular Medicine
- Vol. 31 (1) , 1-14
The clinical potential of PDL-1 pathway and some related micro-RNAs as promising diagnostic markers for breast cancer
Background: Immune checkpoint pathways play important roles in breast cancer (BC) pathogenesis and therapy. Methods: Expression levels of programmed cell death protein 1 (PD-1), cytotoxic T-lymphocyte–associated antigen 4 (CTLA-4), programmed death-ligand 1 (PD-L1), Forkhead box P3 (FOXP3), miR-155, and miR-195 were assessed in the peripheral blood of 90 BC patients compared to 30 healthy controls using quantitative real-time PCR (qRt-PCR). The plasma level of soluble MHC class I chain related-protein B (MIC-B) protein was assessed using the enzyme linked immunosorbent assay (ELISA) technique. The data were correlated to the clinico-pathological characteristics of the patients. Results: There was a significant increase in the expression levels of PDL-1 [17.59 (3.24–123), p < 0.001], CTLA-4 [23.34 (1.3–1267), p = 0.006], PD-1 [10.25 (1–280), p < 0.001], FOXP3 [11.5 (1–234.8), p = 0.001], miR-155 [87.3 (1.5–910), p < 0.001] in BC patients compared to normal controls. The miR-195 was significantly downregulated in BC patients [0.23 (0–0.98, p < 0.001]. The plasma level of MIC-B was significantly increased in the BC patients [0.941 (0.204–6.38) ng/ml], compared to the control group [0.351 (0.211–0.884) ng/mL, p < 0.00]. PDL-1, CTLA-4, PD-1, and FOXP3 achieved a specificity of 100% for distinguishing BC patients, at a sensitivity of 93.3%, 82.2%, 62.2%, and 71.1% respectively. The combined expression of PDL-1 and CTLA-4 scored a 100% sensitivity and 100% specificity for diagnosing BC (p < 0.001). The sensitivity, specificity, and AUC of miR-155 were 88.9%, 96.7%, and 0.934; respectively (p < 0.001). While those of miR-195 were 73.3%, 60%, and 0.716; respectively (p = 0.001). MIC-B expression showed a 77.8% sensitivity, 80% specificity, and 0.811 AUC at a cutoff of 1.17 ng/ml (p < 0.001). Combined expression of miR-155 and miR-195 achieved a sensitivity of 91.1%, a specificity of 96.7%, and AUC of 0.926 (p < 0.001). Multivariate analysis showed that PDL-1 (OR:13.825, p = 0.004), CTLA-4 (OR: 20.958, p = 0.010), PD-1(OR:10.550, p = 0.044), MIC-B (OR: 17.89, p = 0.003), miR-155 (OR: 211.356, P < 0.001), and miR-195(OR:0.006, P < 0.001) were considered as independent risk factors for BC. Conclusions: The PB levels of PDL-1, CTLA-4, PD-1, FOXP3, MIC-B, miR-155, and miR-195 could be used as promising diagnostic markers for BC patients.
- 19 March 2025
- Published by Springer Nature in Molecular Medicine
- Vol. 31 (1) , 1-14
Open AccessThe clinical potential of PDL-1 pathway and some related micro-RNAs as promising diagnostic markers for breast cancer
Background: Immune checkpoint pathways play important roles in breast cancer (BC) pathogenesis and therapy. Methods: Expression levels of programmed cell death protein 1 (PD-1), cytotoxic T-lymphocyte–associated antigen 4 (CTLA-4), programmed death-ligand 1 (PD-L1), Forkhead box P3 (FOXP3), miR-155, and miR-195 were assessed in the peripheral blood of 90 BC patients compared to 30 healthy controls using quantitative real-time PCR (qRt-PCR). The plasma level of soluble MHC class I chain related-protein B (MIC-B) protein was assessed using the enzyme linked immunosorbent assay (ELISA) technique. The data were correlated to the clinico-pathological characteristics of the patients. Results: There was a significant increase in the expression levels of PDL-1 [17.59 (3.24–123), p < 0.001], CTLA-4 [23.34 (1.3–1267), p = 0.006], PD-1 [10.25 (1–280), p < 0.001], FOXP3 [11.5 (1–234.8), p = 0.001], miR-155 [87.3 (1.5–910), p < 0.001] in BC patients compared to normal controls. The miR-195 was significantly downregulated in BC patients [0.23 (0–0.98, p < 0.001]. The plasma level of MIC-B was significantly increased in the BC patients [0.941 (0.204–6.38) ng/ml], compared to the control group [0.351 (0.211–0.884) ng/mL, p < 0.00]. PDL-1, CTLA-4, PD-1, and FOXP3 achieved a specificity of 100% for distinguishing BC patients, at a sensitivity of 93.3%, 82.2%, 62.2%, and 71.1% respectively. The combined expression of PDL-1 and CTLA-4 scored a 100% sensitivity and 100% specificity for diagnosing BC (p < 0.001). The sensitivity, specificity, and AUC of miR-155 were 88.9%, 96.7%, and 0.934; respectively (p < 0.001). While those of miR-195 were 73.3%, 60%, and 0.716; respectively (p = 0.001). MIC-B expression showed a 77.8% sensitivity, 80% specificity, and 0.811 AUC at a cutoff of 1.17 ng/ml (p < 0.001). Combined expression of miR-155 and miR-195 achieved a sensitivity of 91.1%, a specificity of 96.7%, and AUC of 0.926 (p < 0.001). Multivariate analysis showed that PDL-1 (OR:13.825, p = 0.004), CTLA-4 (OR: 20.958, p = 0.010), PD-1(OR:10.550, p = 0.044), MIC-B (OR: 17.89, p = 0.003), miR-155 (OR: 211.356, P < 0.001), and miR-195(OR:0.006, P < 0.001) were considered as independent risk factors for BC. Conclusions: The PB levels of PDL-1, CTLA-4, PD-1, FOXP3, MIC-B, miR-155, and miR-195 could be used as promising diagnostic markers for BC patients.